Skip to main content
. 2010 Sep 7;6:803–811. doi: 10.2147/vhrm.s13441

Table 3.

Shift table for added antihypertensive treatment at baseline and for cumulative changes at the last documented visit (safety population)

Olmesartan-amlodipine 20/5 mg at last documented visit
Olmesartan-amlodipine 40/5 mg at last documented visit
Olmesartan-amlodipine 40/10 mg at last documented visit
Total (baseline)*
n % n % n % n %
Olmesartan-amlodipine 20/5 mg at baseline 2877 37.0 817 10.5 301 3.8 3955 51.4
Olmesartan-amlodipine 40/5 mg at baseline 132 1.7 1736 22.3 538 6.9 2406 31.0
Olmesartan-amlodipine 40/10 mg at baseline 50 0.6 77 0.9 1233 15.8 1360 17.5
Total (follow-up) 3059 39.4 2630 33.8 2072 26.6

Note:

*

Add up to 99.9% because of rounding.